You can only be surprised by this if you’ve been living under a rock for the past 5 years. It is, as they say, a self evident truth that the majority of medical cannabis products and CBD products fail to meet required standards and furthers the argument that medicinal cannabis is in many cases a furphy ( not all.. but many)
Medicinal cannabis companies have learnt from experience in the US and Canada that a regulated adult use market puts them in the back seat which is why you’ll see them fight it tooth and nail in Australia. Luckily for them the lack of education on the subject in Australia is phenomenal at the political level so they’ll have no problem persuading those they need to, to perpetuate a black market that benefits no one except medicinal cannabis companies, their shareholders and law & order politicians.
THE TEST RESULTS
- Bedrocan Dried Cannabis Flos for Inhalation – 74.9%
- Spectrum Blue Cannabis Oil – 87.1%
- LGP Classic 20:5 Cannabis Oil – 88.3%
- Althea Jasper Cannabis Oil – 111.2%
- Althea Capilano Cannabis Oil – 110.1%
The TGA has issued warnings and reminded the relevant companies of the penalties of not conforming to TGO93.
These remaining 17 products all fell in line with the requirements.
From what we know, this is the first publication of testing results released by the TGA, likely the first of many.
Cannabiz Australia report
Almost a quarter of 22 medical cannabis products tested by the Therapeutic Goods Administration failed to comply with required standards, data has revealed.
Laboratory analysis found five products were either stronger or weaker than they should have been, with suppliers warned that another “failed batch” would be in breach of the Therapeutics Goods Act.
The TGA announced in March that it would undertake an audit of unregistered medical cannabis products supplied through the Special Access Scheme. The TGA said importers or suppliers of products that do not comply with standards “may be subject to a range of regulatory compliance actions, including civil and criminal penalties”.
The audit, which was carried out in July and August, requested samples of the top 25 products by volume supplied through the SAS. Three were no longer available, leaving the TGA to test 22.
The lab analysis focused on whether the potency of the products matched that stated by the manufacturer on their Therapeutic Goods Order 93 (TGO93) declaration. TGO93 sets maximum upper and lower limits for cannabis product potency which vary slightly depending on the product type. For example, if a manufacturer declares that their oil product contains 100mg/ml of CBD, it must contain no less than 90mg/ml and no more than 110mg/ml.
Of the five samples found to breach the requirements, three failed to meet the lower limit while two “marginally” exceeded the TGO93 declaration.